$122.94
0.230.19%
近くで: Nov 13, 4:00 PM EST
$122.94
N/A
時間外: 4:00 PM EST
Benzinga
Benzinga
Benzinga
土曜日, 11 14
Benzinga
© 2026 Benzinga | All Rights Reserved
Haemonetics (HAE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Nov 5, 2026 | $1.35 | $1.29 | 4.65 % |
| Q1 | Aug 6, 2026 | $1.14 | $1.09 | 4.59 % |
| Q4 | May 7, 2026 | $1.29 | $1.27 | 1.57 % |
| Q3 | Feb 5, 2026 | $1.31 | $1.26 | 3.97 % |
Quarterly Revenue (Billions)
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Nov 5, 2026 | $357.76M | $345.48M | 3.55 % |
| Q1 | Aug 6, 2026 | $339.38M | $329.19M | 3.10 % |
| Q4 | May 7, 2026 | $346.35M | $337.12M | 2.74 % |
| Q3 | Feb 5, 2026 | $338.97M | $333.30M | 1.70 % |
Haemonetics (HAE) は、11 5, 2026日にfiscal yearの2027に関するガイダンスを直近で発表しました。同社は当期の売上高を$1.44B - $1.48Bの範囲と予想しています。
以前のガイダンスと比較して、Haemoneticsは売上高予測を以前の範囲である引き上げから$1.4B - $1.44Bに引き上げました。
Haemoneticsは、17から2 7, 2023の間に11 5, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 9 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '27 | Q1 '27 | Q4 '26 | Q3 '26 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.29 | $1.09 | $1.27 | $1.26 |
| Actual | $1.35 | $1.14 | $1.29 | $1.31 |
| Surprise | +4.65% | +4.59% | +1.57% | +3.97% |
| Revenue | ||||
| Estimate | $345.5M | $329.2M | $337.1M | $333.3M |
| Actual | $357.8M | $339.4M | $346.4M | $339.0M |
| Surprise | +3.55% | +3.10% | +2.74% | +1.70% |
| Metric | Q3 '27E | Q4 '27E | Q1 '28E | Q2 '28E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.27 | $1.57 | $1.32 | $1.57 |
| Revenue | ||||
| Consensus | $357.6M | $387.2M | — | — |